Phenotypic and Functional Consequences of PLT Binding to Monocytes and Its Association with Clinical Features in SLE.
Adult
Aged
Antibodies, Antinuclear
/ blood
Antigens, CD
/ biosynthesis
Apoptosis
Blood Platelets
/ metabolism
Female
Flow Cytometry
HLA-DR Antigens
/ biosynthesis
Humans
Interleukin-10
/ metabolism
Lupus Erythematosus, Systemic
/ blood
Male
Membrane Glycoproteins
/ biosynthesis
Middle Aged
Monocytes
/ drug effects
Neutrophils
/ pathology
Phagocytosis
Phenotype
Tumor Necrosis Factor-alpha
/ metabolism
immune modulation
lupus
monocytes
platelets
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
29 Apr 2021
29 Apr 2021
Historique:
received:
18
03
2021
revised:
21
04
2021
accepted:
26
04
2021
entrez:
5
5
2021
pubmed:
6
5
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Platelets (PLTs) can modulate the immune system through the release of soluble mediators or through interaction with immune cells. Monocytes are the main immune cells that bind with PLTs, and this interaction is increased in several inflammatory and autoimmune conditions, including systemic lupus erythematosus (SLE). Our aim was to characterize the phenotypic and functional consequences of PLT binding to monocytes in healthy donors (HD) and in SLE and to relate it to the pathogenesis of SLE. We analyzed the phenotypic and functional features of monocytes with non-activated and activated bound PLTs by flow cytometry. We observed that monocytes with bound PLTs and especially those with activated PLTs have an up-regulated HLA-DR, CD86, CD54, CD16 and CD64 expression. Monocytes with bound PLTs also have an increased capacity for phagocytosis, though not for efferocytosis. In addition, monocytes with bound PLTs have increased IL-10, but not TNF-α, secretion. The altered phenotypic and functional features are comparable in SLE and HD monocytes and in bound PLTs. However, the percentages of monocytes with bound PLTs are significantly higher in SLE patients and are associated with undetectable levels of anti-dsDNA antibodies and hematuria, and with normal C3 and albumin/creatinine levels. Our results suggest that PLTs have a modulatory influence on monocytes and that this effect may be highlighted by an increased binding of PLTs to monocytes in autoimmune conditions.
Identifiants
pubmed: 33947017
pii: ijms22094719
doi: 10.3390/ijms22094719
pmc: PMC8125177
pii:
doi:
Substances chimiques
Antibodies, Antinuclear
0
Antigens, CD
0
HLA-DR Antigens
0
IL10 protein, human
0
Membrane Glycoproteins
0
P-selectin ligand protein
0
Tumor Necrosis Factor-alpha
0
Interleukin-10
130068-27-8
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Instituto de Salud Carlos III
ID : PI17/00072
Organisme : Instituto de Salud Carlos III
ID : PI20/00184
Références
Mediators Inflamm. 2019 Mar 3;2019:2473164
pubmed: 30944545
Eur Cytokine Netw. 1993 Nov-Dec;4(6):421-7
pubmed: 8186374
Front Immunol. 2015 Jan 06;5:678
pubmed: 25610439
Br J Haematol. 2001 Nov;115(2):451-9
pubmed: 11703349
J Leukoc Biol. 2006 Mar;79(3):499-507
pubmed: 16415171
Circulation. 2002 May 7;105(18):2166-71
pubmed: 11994250
Blood. 2005 Oct 1;106(7):2417-23
pubmed: 15961512
Arthritis Rheum. 2000 Aug;43(8):1790-800
pubmed: 10943869
Rheumatology (Oxford). 2005 Sep;44(9):1101-7
pubmed: 15928001
PLoS One. 2011;6(10):e25595
pubmed: 22022418
Innate Immun. 2012 Feb;18(1):124-39
pubmed: 21088050
J Rheumatol. 1992 Oct;19(10):1551-8
pubmed: 1464867
Blood. 2014 May 1;123(18):2759-67
pubmed: 24585776
J Immunol. 2002 Jun 15;168(12):6152-8
pubmed: 12055227
Nat Immunol. 2013 Aug;14(8):785-92
pubmed: 23770641
J Clin Invest. 1989 Aug;84(2):546-52
pubmed: 2474571
J Thromb Haemost. 2008 Jun;6(6):986-94
pubmed: 18363812
J Leukoc Biol. 1998 Apr;63(4):469-76
pubmed: 9544577
Clin Immunol. 2002 Apr;103(1):54-62
pubmed: 11987985
Thromb Haemost. 2015 May;113(5):1035-45
pubmed: 25716539
Arthritis Rheum. 1998 Jul;41(7):1241-50
pubmed: 9663482
J Clin Invest. 1996 Mar 15;97(6):1525-34
pubmed: 8617886
Platelets. 2016 Sep;27(6):583-92
pubmed: 27078265
Platelets. 2009 Nov;20(7):493-7
pubmed: 19852688
J Immunol. 2001 Sep 1;167(5):2479-86
pubmed: 11509586
Nat Rev Rheumatol. 2018 Mar 21;14(4):195-213
pubmed: 29559714
J Immunol. 2009 Jun 15;182(12):7997-8004
pubmed: 19494325
Arthritis Rheum. 2011 Jan;63(1):212-8
pubmed: 20954190
Nat Rev Rheumatol. 2012 Sep;8(9):534-42
pubmed: 22868927
J Immunol. 1991 Jul 1;147(1):117-23
pubmed: 2051017
Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):193-9
pubmed: 14615387
J Thromb Haemost. 2014 Nov;12(11):1764-75
pubmed: 25224706
Cell Mol Immunol. 2015 Jul;12(4):435-43
pubmed: 25109683
J Clin Immunol. 2004 Jan;24(1):62-5
pubmed: 14997035
Circulation. 2001 Sep 25;104(13):1533-7
pubmed: 11571248
Blood. 2006 Jul 1;108(1):167-76
pubmed: 16514062
Mediators Inflamm. 2017;2017:1463216
pubmed: 28592915
Front Cardiovasc Med. 2019 Aug 07;6:109
pubmed: 31448291
Sci Rep. 2015 Sep 11;5:13886
pubmed: 26358827
Cytokine. 2012 Oct;60(1):257-65
pubmed: 22795952
Open Access Rheumatol. 2019 Mar 26;11:61-65
pubmed: 30988645
J Leukoc Biol. 2009 Feb;85(2):195-204
pubmed: 18948548
Nat Rev Immunol. 2011 Apr;11(4):264-74
pubmed: 21436837
Int Immunol. 2019 Oct 16;31(11):687-696
pubmed: 31063541
Front Immunol. 2017 Oct 05;8:1227
pubmed: 29051759
Arch Immunol Ther Exp (Warsz). 2010 Oct;58(5):355-64
pubmed: 20676786
Clin Immunol. 2005 Dec;117(3):271-9
pubmed: 16316784
J Immunol. 2013 Oct 15;191(8):4059-67
pubmed: 24048901
J Exp Med. 2000 Jul 17;192(2):193-204
pubmed: 10899906
Mediators Inflamm. 2015;2015:328078
pubmed: 26063969
Front Immunol. 2013 Feb 04;4:23
pubmed: 23382732
Arterioscler Thromb Vasc Biol. 2000 Dec;20(12):2702-8
pubmed: 11116075
Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):e2-3
pubmed: 18094392
Arthritis Res Ther. 2014 Nov 18;16(6):478
pubmed: 25404518
Mol Immunol. 2011 Jan;48(4):691-6
pubmed: 21168221
Int Arch Allergy Immunol. 2013;160(2):152-60
pubmed: 23018521
J Exp Med. 1990 Dec 1;172(6):1625-31
pubmed: 2124252
J Immunol. 2000 Sep 1;165(5):2764-72
pubmed: 10946308
Atherosclerosis. 2004 Oct;176(2):321-5
pubmed: 15380455
Transfus Med Hemother. 2016 Mar;43(2):78-88
pubmed: 27226790
J Clin Invest. 1994 Jan;93(1):424-8
pubmed: 8282815
Clin Exp Immunol. 1984 Jan;55(1):125-32
pubmed: 6229371
Scand J Immunol. 2008 Feb;67(2):152-9
pubmed: 18201370
J Leukoc Biol. 2009 Nov;86(5):1119-24
pubmed: 19703898
Blood. 2007 Jun 1;109(11):4803-5
pubmed: 17299089
Lupus. 1995 Oct;4(5):393-5
pubmed: 8563734
Arterioscler Thromb Vasc Biol. 2000 Oct;20(10):2322-8
pubmed: 11031222
J Thromb Haemost. 2011 May;9(5):1007-19
pubmed: 21320284
Cell. 1989 Oct 20;59(2):305-12
pubmed: 2478294
J Thromb Haemost. 2006 Apr;4(4):874-81
pubmed: 16634758
Biochem Biophys Res Commun. 2005 Apr 1;329(1):345-55
pubmed: 15721313
Cancer Immunol Immunother. 2021 Jun;70(6):1691-1704
pubmed: 33388994
Platelets. 2013;24(4):255-62
pubmed: 22671308
J Immunol. 2006 Jun 1;176(11):6991-9
pubmed: 16709860